{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T22:51:56Z","timestamp":1767135116541,"version":"build-2238731810"},"update-to":[{"DOI":"10.1002\/14651858.cd009045","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2012,9,12]],"date-time":"2012-09-12T00:00:00Z","timestamp":1347408000000}}],"reference-count":87,"publisher":"Wiley","issue":"9","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd009045.pub2","type":"journal-article","created":{"date-parts":[[2012,9,4]],"date-time":"2012-09-04T18:38:34Z","timestamp":1346783914000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Bendamustine for patients with indolent B cell lymphoid malignancies including chronic lymphocytic leukaemia"],"prefix":"10.1002","volume":"2012","author":[{"given":"Liat","family":"Vidal","sequence":"first","affiliation":[{"name":"Beilinson Hospital, Rabin Medical Center; Department of Medicine E; 39 Jabotinski Street Petah Tikva Israel 49100"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anat","family":"Gafter-Gvili","sequence":"additional","affiliation":[{"name":"Beilinson Hospital, Rabin Medical Center; Department of Medicine E; 39 Jabotinski Street Petah Tikva Israel 49100"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ronit","family":"Gurion","sequence":"additional","affiliation":[{"name":"Beilinson Hospital, Rabin Medical Center; Institute of Hematology, Davidoff Center; 39 Jabotinski Street Petah Tikva Israel 49100"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pia","family":"Raanani","sequence":"additional","affiliation":[{"name":"Beilinson Hospital, Rabin Medical Center; Institute of Hematology, Davidoff Center; 39 Jabotinski Street Petah Tikva Israel 49100"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Dreyling","sequence":"additional","affiliation":[{"name":"Klinikum der Universit\u00e4t M\u00fcnchen-Gro\u00dfhadern; Medizinische Klinik III; M\u00fcnchen Germany 81366"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ofer","family":"Shpilberg","sequence":"additional","affiliation":[{"name":"Beilinson Hospital, Rabin Medical Center; Institute of Hematology, Davidoff Center; 39 Jabotinski Street Petah Tikva Israel 49100"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2012,9,12]]},"reference":[{"issue":"2","key":"10.1002\/14651858.CD009045.pub2-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s00432-005-0023-2","article-title":"Bendamustine, vincristine and prednisone (BOP) versus cyclophosphamide, vincristine and prednisone (COP) in advanced indolent non-Hodgkin's lymphoma and mantle cell lymphoma: results of a randomised phase III trial (OSHO# 19)","volume":"132","author":"Herold","year":"2006","journal-title":"Journal of Cancer Research and Clinical Oncology"},{"key":"10.1002\/14651858.CD009045.pub2-BIB0002|cit2","unstructured":"Knauf U Lissichkov T Aldoud A Herbrecht R Liberati A Loscertales J Bendamustine versus chlorambucil in treatment- naive patients with chronic lymphocytic leukemia: updated results of an international phase III study Haematologica 2009 141. Abstract 0355"},{"issue":"11","key":"10.1002\/14651858.CD009045.pub2-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"609a","DOI":"10.1182\/blood.V110.11.2043.2043","article-title":"Bendamustine versus chlorambucil in treatment-Naive Patients with B-Cell chronic lymphocytic leukemia (B-CLL): Results of an International phase III study","volume":"110","author":"Knauf","year":"2007","journal-title":"Blood"},{"issue":"26","key":"10.1002\/14651858.CD009045.pub2-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"4378","DOI":"10.1200\/JCO.2008.20.8389","article-title":"Phase III randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemia","volume":"27","author":"Knauf","year":"2009","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD009045.pub2-BIB0005|cit5","doi-asserted-by":"crossref","unstructured":"Knauf WU Lissitchkov T Aldaoud A Liberati A Loscertales J Herbrecht R Bendamustine versus chlorambucil as first-line treatment in B cell chronic lymphocytic leukemia: an updated analysis from an International phase III study Blood 2008 728. Abstract No. 2091","DOI":"10.1182\/blood.V112.11.2091.2091"},{"key":"10.1002\/14651858.CD009045.pub2-BIB0006|cit6","doi-asserted-by":"crossref","unstructured":"Knauf WU Lissitchkov T Herbrecht R Loscertales J Aldaoud A Merkle K Bendamustine versus chlorambucil in treatment-naive B-CLL patients Blood 2004 287b","DOI":"10.1182\/blood.V104.11.4817.4817"},{"key":"10.1002\/14651858.CD009045.pub2-BIB0007|cit7","doi-asserted-by":"crossref","unstructured":"Knauf WU Lissitchkov T Raoul H Aldaoud A Merkle KH Bendamustine versus chlorambucil in treatment-naive B-CLL patients - results of a safety analysis Blood 2003 357b","DOI":"10.1182\/blood.V104.11.4817.4817"},{"key":"10.1002\/14651858.CD009045.pub2-BIB0008|cit8","unstructured":"Hinke A Niederle N Bendamustine versus fludarabine in chronic lymphocytic leukemia http:\/\/clinicaltrials.gov\/ct2\/show\/NCT01423032"},{"key":"10.1002\/14651858.CD009045.pub2-BIB0009|cit9","first-page":"405","article-title":"Bendamustine plus rituximab Is superior in respect of progression free survival and CR rate when compared to CHOP plus rituximab as first-line treatment of patients with advanced follicular, indolent, and mantle cell lymphomas: final results of a randomized phase III study of the StiL (study group indolent lymphomas, Germany)","volume":"114","author":"Rummel","year":"2009","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"10.1002\/14651858.CD009045.pub2-BIB0010|cit10","doi-asserted-by":"crossref","unstructured":"Rummel MJ von Gruenhagen U Niederle N Ballo H Weidmann E Welslau M Bendamustine plus rituximab versus CHOP plus rituximab in the first-line treatment of patients with follicular, indolent and mantle cell lymphomas: results of a randomized phase III study of the study group indolent lymphomas (StiL) Blood 2008 900. [Abstract No. 2596]","DOI":"10.1182\/blood.V112.11.2596.2596"},{"key":"10.1002\/14651858.CD009045.pub2-BIB0011|cit11","doi-asserted-by":"crossref","unstructured":"Rummel MJ von Gruenhagen U Niederle N Rothmann F Ballo H Weidmann E Bendamustine plus rituximab versus CHOP plus rituximab in the first line treatment of patients with indolent and mantle cell lymphomas first interim results of a randomized phase III study of the StiL (study group indolent lymphomas, Germany) Blood 2007 120a","DOI":"10.1182\/blood.V110.11.385.385"},{"key":"10.1002\/14651858.CD009045.pub2-BIB0012|cit12","doi-asserted-by":"crossref","unstructured":"Rummel JM Kaiser U Balser C Stauch BM Brugger W Welslau M Bendamustine plus rituximab versus fludarabine plus rituximab In patients with relapsed follicular, indolent and mantle cell lymphomas - final results of the randomized phase III study NHL 2-2003 on behalf of the StiL (study group indolent lymphomas, Germany) Blood (ASH Annual Meeting Abstracts) 2010 856","DOI":"10.1182\/blood.V116.21.856.856"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD009045.pub2-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1016\/j.clml.2011.02.006","article-title":"Chlorambucil--still not bad: a reappraisal","volume":"11","author":"Catovsky","year":"2011","journal-title":"Clinical lymphoma, myeloma & leukemia"},{"issue":"6","key":"10.1002\/14651858.CD009045.pub2-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"452","DOI":"10.3816\/CLML.2010.n.079","article-title":"Bendamustine produces durable responses with an acceptable safety profile in patients with rituximab-refractory indolent non-Hodgkin lymphoma","volume":"10","author":"Cheson","year":"2010","journal-title":"Clinical lymphoma, myeloma & leukemia"},{"issue":"11","key":"10.1002\/14651858.CD009045.pub2-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"e300","DOI":"10.1016\/j.leukres.2010.06.011","article-title":"Efficacy of bendamustine as salvage treatment in an heavily pre-treated Hodgkin lymphoma","volume":"34","author":"D'Elia","year":"2010","journal-title":"Leukemia Research"},{"issue":"10","key":"10.1002\/14651858.CD009045.pub2-BIB0016|cit16","first-page":"1300A","article-title":"Bendamustine in relapsed or refractory chronic lymphocytic leukemia","volume":"90","author":"Ferrajoli","year":"2005","journal-title":"Haematologica"},{"issue":"2","key":"10.1002\/14651858.CD009045.pub2-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1200\/JCO.2007.12.5070","article-title":"Bendamustine in patients with rituximab-refractory indolent and transformed non-Hodgkin's lymphoma: results from a phase II multicenter, single-agent study","volume":"26","author":"Friedberg","year":"2008","journal-title":"Journal of Clinical Oncology"},{"issue":"1","key":"10.1002\/14651858.CD009045.pub2-BIB0018|cit18","first-page":"40","article-title":"Initial experiences with a new cytostatic agent (IMET 3106=1-methyl-2-(p-(bis-(beta-chlorethyl)-amino)-phenyliminomethyl)-quinolinium chloride)","volume":"40","author":"Hesse","year":"1972","journal-title":"Archiv fur Geschwulstforschung"},{"issue":"43","key":"10.1002\/14651858.CD009045.pub2-BIB0019|cit19","first-page":"2058","article-title":"Clinical report on the cytostatic agent cytostasan","volume":"27","author":"Hesse","year":"1972","journal-title":"Deutsche Gesundheitswesen"},{"issue":"1","key":"10.1002\/14651858.CD009045.pub2-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1007\/s004320000180","article-title":"Bendamustine monotherapy in advanced and refractory chronic lymphocytic leukemia","volume":"127","author":"Kath","year":"2001","journal-title":"Journal of Cancer Research and Clinical Oncology"},{"issue":"1","key":"10.1002\/14651858.CD009045.pub2-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"149","DOI":"10.3109\/10428190903275602","article-title":"Weekly treatment with a combination of bortezomib and bendamustine in relapsed or refractory indolent non-Hodgkin lymphoma","volume":"51","author":"Moosmann","year":"2010","journal-title":"Leukemia and Lymphoma"},{"issue":"1","key":"10.1002\/14651858.CD009045.pub2-BIB0022|cit22","first-page":"92","article-title":"A new highly effective therapy of indolent non-Hodgkin lymphomas with bendamustine","volume":"26","author":"No authors","year":"2003","journal-title":"Onkologie"},{"issue":"1299","key":"10.1002\/14651858.CD009045.pub2-BIB0023|cit23","first-page":"91","article-title":"Bendamustine (Treanda) for CLL and NHL","volume":"50","author":"No authors","year":"2008","journal-title":"Medical Letter on Drugs and Therapeutics"},{"issue":"27","key":"10.1002\/14651858.CD009045.pub2-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"4473","DOI":"10.1200\/JCO.2008.17.0001","article-title":"Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin's lymphoma","volume":"26","author":"Robinson","year":"2008","journal-title":"Journal of Clinical Oncology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD009045.pub2-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"S24","DOI":"10.1053\/j.seminhematol.2011.03.004","article-title":"Bendamustine's emerging role in the management of lymphoid malignancies","volume":"48","author":"Rummel","year":"2011","journal-title":"Seminars in Hematology"},{"issue":"1","key":"10.1002\/14651858.CD009045.pub2-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"133","DOI":"10.3816\/CLML.2011.n.030","article-title":"Bendamustine therapy in patients with relapsed or refractory Waldenstrom's macroglobulinemia","volume":"11","author":"Treon","year":"2011","journal-title":"Clinical Lymphoma, Myeloma & Leukemia"},{"key":"10.1002\/14651858.CD009045.pub2-BIB0027|cit27","unstructured":"Study of bendamustine hydrochloride and rituximab (BR) compared with R-CVP or R-CHOP in the first-line treatment of patients with advanced indolent non-Hodgkin's lymphoma (NHL) or mantle cell lymphoma (MCL) - referred to as the BRIGHT study Ongoing study April 2009"},{"key":"10.1002\/14651858.CD009045.pub2-BIB0028|cit28","unstructured":"Bendamustine hydrochloride injection for initial treatment of chronic lymphocytic leukemia Ongoing study March 2010"},{"key":"10.1002\/14651858.CD009045.pub2-BIB0029|cit29","unstructured":"Fludarabine, cyclophosphamide, and rituximab or bendamustine and rituximab in treating patients with previously untreated B cell chronic lymphocytic leukaemia Ongoing study September 2008"},{"key":"10.1002\/14651858.CD009045.pub2-BIB0030|cit30","unstructured":"A trial to investigate the efficacy of bendamustine in patients with indolent non-Hodgkin's lymphoma (NHL) refractory to rituximab Ongoing study February 2011"},{"key":"10.1002\/14651858.CD009045.pub2-BIB0031|cit31","unstructured":"A study of mabThera added to bendamustine or chlorambucil in patients with chronic lymphocytic leukemia (MaBLe) Ongoing study March 2010"},{"issue":"9383","key":"10.1002\/14651858.CD009045.pub2-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/S0140-6736(03)14110-4","article-title":"Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: a randomised controlled trial","volume":"362","author":"Ardeshna","year":"2003","journal-title":"Lancet"},{"issue":"8","key":"10.1002\/14651858.CD009045.pub2-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1200\/JCO.1998.16.8.2780","article-title":"New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project","volume":"16","author":"Armitage","year":"1998","journal-title":"Journal of Clinical Oncology"},{"issue":"1","key":"10.1002\/14651858.CD009045.pub2-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1002\/1097-0142(19810701)48:1<198::AID-CNCR2820480131>3.0.CO;2-V","article-title":"A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis","volume":"48","author":"Binet","year":"1981","journal-title":"Cancer"},{"issue":"9583","key":"10.1002\/14651858.CD009045.pub2-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/S0140-6736(07)61125-8","article-title":"Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial","volume":"37","author":"Catovsky","year":"2007","journal-title":"Lancet"},{"issue":"5","key":"10.1002\/14651858.CD009045.pub2-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","article-title":"Revised response criteria for malignant lymphoma","volume":"25","author":"Cheson","year":"2007","journal-title":"Journal of Clinical Oncology"},{"issue":"5","key":"10.1002\/14651858.CD009045.pub2-BIB0037|cit37","first-page":"485","article-title":"In vitro induction of apoptosis of neoplastic cells in low-grade non-Hodgkin's lymphomas using combinations of established cytotoxic drugs with bendamustine","volume":"86","author":"Chow","year":"2001","journal-title":"Haematologica"},{"issue":"10","key":"10.1002\/14651858.CD009045.pub2-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1093\/jnci\/91.10.861","article-title":"Chemotherapeutic options in chronic lymphocytic leukemia: a meta-analysis of the randomized trials","volume":"91","author":"CLL Trialists\u2019 Collaborative Group","year":"1999","journal-title":"Journal of the National Cancer Institute"},{"key":"10.1002\/14651858.CD009045.pub2-BIB0039|cit39","doi-asserted-by":"crossref","DOI":"10.1002\/9780470693926.ch15","article-title":"Statistical methods for examining heterogeneity and combining results from several studies in meta-analysis","volume-title":"Systematic Reviews in Health Care: Meta-analysis in Context","author":"Deeks","year":"2001"},{"key":"10.1002\/14651858.CD009045.pub2-BIB0040|cit40","unstructured":"Deeks JJ Higgins JPT Altman DG (editors) Chapter 9: Analysing data and undertaking meta-analyses Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org"},{"key":"10.1002\/14651858.CD009045.pub2-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Controlled Clinical Trials"},{"key":"10.1002\/14651858.CD009045.pub2-BIB0042|cit42","first-page":"330","article-title":"Bendamustine in combination with rituximab (BR) for patients with relapsed chronic lymphocytic leukemia (CLL): a multicentre phase II trial of the German CLL Study Group (GCLLSG)","volume":"112","author":"Fischer","year":"2008","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"issue":"8","key":"10.1002\/14651858.CD009045.pub2-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1200\/JCO.2008.18.1495","article-title":"Follicular Lymphoma in the United States: First Report of the National LymphoCare Study","volume":"27","author":"Friedberg","year":"2009","journal-title":"Journal of Clinical Oncology"},{"issue":"5","key":"10.1002\/14651858.CD009045.pub2-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1182\/blood.V58.5.920.920","article-title":"Nodular mixed lymphoma: results of a randomized trial failing to confirm prolonged disease-free survival with COPP chemotherapy","volume":"58","author":"Glick","year":"1981","journal-title":"Blood"},{"issue":"10","key":"10.1002\/14651858.CD009045.pub2-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1200\/JCO.2005.03.7952","article-title":"Phase III intergroup study of fludarabine phosphate compared with cyclophosphamide, vincristine, and prednisone chemotherapy in newly diagnosed patients with stage III and IV low-grade malignant non-Hodgkin's lymphoma","volume":"24","author":"Hagenbeek","year":"2006","journal-title":"Journal of Clinical Oncology"},{"issue":"12","key":"10.1002\/14651858.CD009045.pub2-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"5446","DOI":"10.1182\/blood-2007-06-093906","article-title":"Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the international workshop on chronic lymphocytic leukemia updating the national cancer institute-working group 1996 guidelines","volume":"111","author":"Hallek","year":"2008","journal-title":"Blood"},{"issue":"9747","key":"10.1002\/14651858.CD009045.pub2-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1016\/S0140-6736(10)61381-5","article-title":"Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial","volume":"376","author":"Hallek","year":"2010","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD009045.pub2-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1182\/blood.V94.6.1848","article-title":"Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia","volume":"94","author":"Hamblin","year":"1999","journal-title":"Blood"},{"issue":"5","key":"10.1002\/14651858.CD009045.pub2-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1182\/blood.V84.5.1361.1361","article-title":"A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group","volume":"84","author":"Harris","year":"1994","journal-title":"Blood"},{"issue":"9","key":"10.1002\/14651858.CD009045.pub2-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1097\/00001813-200110000-00003","article-title":"Efficacy and toxicity of bendamustine in patients with relapsed low-grade non-Hodgkin's lymphomas","volume":"12","author":"Heider","year":"2001","journal-title":"Anticancer Drugs"},{"key":"10.1002\/14651858.CD009045.pub2-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD009045.pub2-BIB0052|cit52","unstructured":"Higgins JPT Altman DG Sterne JAC (editors) Chapter 8: Assessing risk of bias in included studies Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org"},{"issue":"23","key":"10.1002\/14651858.CD009045.pub2-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1056\/NEJM198412063112303","article-title":"The natural history of initially untreated low-grade non-Hodgkin's lymphomas","volume":"311","author":"Horning","year":"1984","journal-title":"New England Journal of Medicine"},{"issue":"2","key":"10.1002\/14651858.CD009045.pub2-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1182\/blood-2007-06-095331","article-title":"A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma","volume":"111","author":"Hoster","year":"2008","journal-title":"Blood"},{"issue":"2","key":"10.1002\/14651858.CD009045.pub2-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1182\/blood-2007-06-095331","article-title":"A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma","volume":"111","author":"Hoster","year":"2008","journal-title":"Blood"},{"key":"10.1002\/14651858.CD009045.pub2-BIB0056|cit56","doi-asserted-by":"crossref","unstructured":"Itchaki G Gafter-Gvili A Lahav M Raanani P Vidal L Paul M Anthracycline-containing regimens for treatment of follicular lymphoma in adults: systematic review and meta-analysis Blood (ASH Annual Meeting Abstracts) 2010 2820","DOI":"10.1002\/14651858.CD008909"},{"issue":"1","key":"10.1002\/14651858.CD009045.pub2-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1002\/cncr.24714","article-title":"Bendamustine is effective therapy in patients with rituximab-refractory, indolent B-cell non-Hodgkin lymphoma: results from a Multicenter Study","volume":"116","author":"Kahl","year":"2010","journal-title":"Cancer"},{"issue":"1","key":"10.1002\/14651858.CD009045.pub2-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"102","DOI":"10.3324\/haematol.2009.010298","article-title":"Gene expression factors as predictors of genetic risk and survival in chronic lymphocytic leukemia","volume":"95","author":"Kienle","year":"2010","journal-title":"Haematologica"},{"issue":"2-3","key":"10.1002\/14651858.CD009045.pub2-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1080\/02841860151116303","article-title":"A systematic overview of chemotherapy effects in B-cell chronic lymphocytic leukaemia","volume":"40","author":"Kimby","year":"2001","journal-title":"Acta Oncologica"},{"issue":"24","key":"10.1002\/14651858.CD009045.pub2-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"4649","DOI":"10.1200\/JCO.2002.11.068","article-title":"Randomized phase III study of fludarabine phosphate versus cyclophosphamide, vincristine, and prednisone in patients with recurrent low-grade non-Hodgkin's lymphoma previously treated with an alkylating agent or alkylator-containing regimen","volume":"20","author":"Klasa","year":"2002","journal-title":"Journal of Clinical Oncology"},{"issue":"9","key":"10.1002\/14651858.CD009045.pub2-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1080\/1042819042000223822","article-title":"Fludarabine and bendamustine in refractory and relapsed indolent lymphoma-a multicenter phase I\/II Trial of the East German Society of Hematology and Oncology (OSHO)","volume":"45","author":"Koenigsmann","year":"2004","journal-title":"Leukemia and Lymphoma"},{"issue":"4","key":"10.1002\/14651858.CD009045.pub2-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1200\/JCO.1996.14.4.1282","article-title":"Is radiotherapy curative for stage I and II low-grade follicular lymphoma? Results of a long-term follow-up study of patients treated at Stanford University","volume":"14","author":"MacManus","year":"1996","journal-title":"Journal of Clinical Oncology"},{"issue":"5","key":"10.1002\/14651858.CD009045.pub2-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1002\/cncr.22093","article-title":"Combined cyclophosphamide, vincristine, doxorubicin, and prednisone (CHOP) improves response rates but not survival and has lower hematologic toxicity compared with combined mitoxantrone, chlorambucil, and prednisone (MCP) in follicular and mantle cell lymphomas: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group","volume":"107","author":"Nickenig","year":"2006","journal-title":"Cancer"},{"key":"10.1002\/14651858.CD009045.pub2-BIB0064|cit64","first-page":"1013","article-title":"IMET 3393, gamma-(1-methyl-5-bis-(b-chloroethyl) amine-benzimidazolyl (2)-butyric acid hydrochloride, a new cytostatic agent from the series of benzimidazole-Lost","volume":"110","author":"Ozegowski","year":"1971","journal-title":"Zbl Pharm"},{"key":"10.1002\/14651858.CD009045.pub2-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1002\/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8","article-title":"Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints","volume":"17","author":"Parmar","year":"1998","journal-title":"Statistics in Medicine"},{"issue":"1","key":"10.1002\/14651858.CD009045.pub2-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1200\/jco.2003.05.128","article-title":"Prolonged single-agent versus combination chemotherapy in indolent follicular lymphomas: a study of the cancer and leukemia group B","volume":"21","author":"Peterson","year":"2003","journal-title":"Journal of Clinical Oncology"},{"issue":"2","key":"10.1002\/14651858.CD009045.pub2-BIB0067|cit67","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1182\/blood.V46.2.219.219","article-title":"Clinical staging of chronic lymphocytic leukemia","volume":"46","author":"Rai","year":"1975","journal-title":"Blood"},{"key":"10.1002\/14651858.CD009045.pub2-BIB0068|cit68","unstructured":"The Nordic Cochrane Centre, The Cochrane Collaboration Review Manager (RevMan) 2011"},{"issue":"3","key":"10.1002\/14651858.CD009045.pub2-BIB0069|cit69","doi-asserted-by":"crossref","first-page":"428","DOI":"10.3324\/haematol.2011.053512","article-title":"Systematic review of purine analogue treatment for chronic lymphocytic leukemia: lessons for future trials","volume":"97","author":"CLL Trialists\u2019 Collaborative Group (CLLTCG)","year":"2012","journal-title":"Haematologica"},{"issue":"1","key":"10.1002\/14651858.CD009045.pub2-BIB0070|cit70","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1093\/ije\/31.1.150","article-title":"Development of a highly sensitive search strategy for the retrieval of reports of controlled trials using PubMed","volume":"31","author":"Robinson","year":"2002","journal-title":"International Journal of Epidemiology"},{"issue":"27","key":"10.1002\/14651858.CD009045.pub2-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"4473","DOI":"10.1200\/JCO.2008.17.0001","article-title":"Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin's lymphoma","volume":"26","author":"Robinson","year":"2008","journal-title":"Journal of Clinical Oncology"},{"issue":"4 Suppl 13","key":"10.1002\/14651858.CD009045.pub2-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1053\/sonc.2002.34873","article-title":"In vitro studies with bendamustine: enhanced activity in combination with rituximab","volume":"29","author":"Rummel","year":"2002","journal-title":"Seminars in Oncology"},{"issue":"15","key":"10.1002\/14651858.CD009045.pub2-BIB0073|cit73","doi-asserted-by":"crossref","first-page":"3383","DOI":"10.1200\/JCO.2005.08.100","article-title":"Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin's lymphoma","volume":"23","author":"Rummel","year":"2005","journal-title":"Journal of Clinical Oncology"},{"issue":"5","key":"10.1002\/14651858.CD009045.pub2-BIB0074|cit74","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1001\/jama.1995.03520290060030","article-title":"Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials","volume":"273","author":"Schulz","year":"1995","journal-title":"JAMA"},{"issue":"4","key":"10.1002\/14651858.CD009045.pub2-BIB0075|cit75","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003805.pub2","article-title":"Chemotherapy plus rituximab versus chemotherapy alone for B-cell non-Hodgkin's lymphoma","author":"Schulz","year":"2007","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD009045.pub2-BIB0076|cit76","unstructured":"Sterne JAC Egger M Moher D (editors) Chapter 10: Addressing reporting biases In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Intervention. Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org"},{"issue":"3","key":"10.1002\/14651858.CD009045.pub2-BIB0077|cit77","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004270.pub2","article-title":"Purine antagonists for chronic lymphocytic leukaemia","author":"Steurer","year":"2006","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"4","key":"10.1002\/14651858.CD009045.pub2-BIB0078|cit78","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1097\/00001813-199606000-00007","article-title":"Bendamustine hydrochloride activity against doxorubicin-resistant human breast carcinoma cell lines","volume":"7","author":"Strumberg","year":"1996","journal-title":"Anticancer Drugs"},{"key":"10.1002\/14651858.CD009045.pub2-BIB0079|cit79","volume-title":"World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues","author":"Swerdlow","year":"2008"},{"issue":"29","key":"10.1002\/14651858.CD009045.pub2-BIB0080|cit80","doi-asserted-by":"crossref","first-page":"4648","DOI":"10.1200\/JCO.2006.09.4508","article-title":"Assessment of chronic lymphocytic leukemia and small lymphocytic lymphoma by absolute lymphocyte counts in 2,126 patients: 20 years of experience at the University of Texas M.D. Anderson Cancer Center","volume":"25","author":"Tsimberidou","year":"2007","journal-title":"Journal of Clinical Oncology"},{"issue":"2","key":"10.1002\/14651858.CD009045.pub2-BIB0081|cit81","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006552.pub2","article-title":"Rituximab as maintenance therapy for patients with follicular lymphoma","author":"Vidal","year":"2009","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"10","key":"10.1002\/14651858.CD009045.pub2-BIB0082|cit82","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD009341","article-title":"Chlorambucil for the treatment of patients with chronic lymphocytic leukaemia, or small lymphocytic lymphoma","author":"Vidal","year":"2011","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"2","key":"10.1002\/14651858.CD009045.pub2-BIB0083|cit83","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1080\/10428190290006107","article-title":"Bendamustine mitoxantrone and rituximab (BMR): a new effective regimen for refractory or relapsed indolent lymphomas","volume":"43","author":"Weide","year":"2002","journal-title":"Leukemia and Lymphoma"},{"issue":"12","key":"10.1002\/14651858.CD009045.pub2-BIB0084|cit84","doi-asserted-by":"crossref","first-page":"2445","DOI":"10.1080\/10428190400004521","article-title":"Bendamustine\/mitoxantrone\/rituximab (BMR): a very effective, well tolerated outpatient chemoimmunotherapy for relapsed and refractory CD20-positive indolent malignancies. Final results of a pilot study","volume":"45","author":"Weide","year":"2004","journal-title":"Leukemia and Lymphoma"},{"issue":"5","key":"10.1002\/14651858.CD009045.pub2-BIB0085|cit85","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1016\/S0360-3016(01)01747-3","article-title":"Long-term results with radiotherapy for stage I-II follicular lymphomas","volume":"51","author":"Wilder","year":"2001","journal-title":"International Journal of Radiation Oncology, Biology, Physics"},{"key":"10.1002\/14651858.CD009045.pub2-BIB0086|cit86","first-page":"11","article-title":"The treatment of indolent lymphomas: watchful waiting vs aggressive combined modality treatment","volume":"25","author":"Young","year":"1988","journal-title":"Seminars in Hematology"},{"issue":"11","key":"10.1002\/14651858.CD009045.pub2-BIB0087|cit87","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1080\/10428190412331283260","article-title":"Fludarabine in comparison to alkylator-based regimen as induction therapy for chronic lymphocytic leukemia: a systematic review and meta-analysis","volume":"45","author":"Zhu","year":"2004","journal-title":"Leukemia and Lymphoma"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1002\/14651858.CD009045.pub2\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,4]],"date-time":"2024-09-04T12:47:27Z","timestamp":1725454047000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD009045.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Haematological Malignancies Group","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2012,9,12]]},"references-count":87,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2012,9]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd009045.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,9,12]]}}}